Researchers at the Icahn School of Medicine at Mount Sinai in New York found once-daily ribavirin treatment did not increase the risk of adverse gastrointestinal events in hepatitis C patients being treated with triple therapy. The results were presented at the International Conference on Viral Hepatitis.
Study: Single daily ribavirin dose doesn't increase adverse effects
SmartBrief Job Listings for Health Care
|Sr. Medical Device Reimbursement Specialist - Regional||
|Fort Worth , TX|
|Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group||
|Clinical Trials Agreements Specialist (209955)||
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
|SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST||
Matheson Tri-Gas, Inc.
ASAHI INTECC, Orange County CA R&D Center
|Santa Ana, CA|